Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

AIDS

Volumn 28, Issue 2, 2014, Pages 187-199

  Ryom, Lene ^a   Mocroft, Amanda ^b   Kirk, Ole ^a   Ross, Michael ^c   Reiss, Peter ^d   Fux, Christophe A ^e   Morlat, Philippe ^f   Moranne, Olivier ^g   Smith, Colette ^b   El Sadr, Wafaa ^h   Law, Matthew ⁱ   Lundgren, Jens D ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

^f HÔPITAL SAINT ANDRÉ   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h Harlem Hospital ^*  (United States)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Advanced chronic kidney disease; Adverse events; Antiretroviral agents; End stage renal disease; HIV; Nephrotoxicity; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG EXPOSURE; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROTOXICITY; PRIORITY JOURNAL;

ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84892373117     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000042     Document Type: Article

References (41)

1. Lescure FX, Flateau C, Pacanowski J, Brocheriou I, Rondeau E, Girard PM, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant 2012; 27:2349-2355.
2. Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS 2004; 18:1089-1099.
3. Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, et al. Hepatitis B and C Co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012; 7:e40245.
4. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24:1877-1886.
5. Wyatt CM, Klotman PE. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf 2006; 5:275-287.
6. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-1678.
7. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007; 21:2435-2443.
8. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIVinfected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
9. Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26:1907-1915.
10. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
11. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546.
12. Shah S, Weber-Shrikant E, Panesar M. Discontinuation of antiretroviral therapy causing progression to end-stage renal disease in HIV patient diagnosed with immune complex 'lupuslike' glomerulonephritis. Clin Kidney J 2012; 5:276-278.
13. Mwafongo A, Nkanaunena K, Hosseinipour M, Lockman S, Hughes M, Currier J, et al. Renal insufficiency among women treated with tenofovir/emtricitabine/ lopinavir/ritonavir or tenofovir/emtricitabine/nevirapine, #152, CROI 2013. Atlanta: Georgia; 2013.
14. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Exposure to antiretrovirals (ARVs) and risk of renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207:1359-1369.
15. Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabie A, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol 2011; 6:1700-1707.
16. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-875.
17. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-1201.
18. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
19. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089-2100.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
21. Delanaye P, Mariat C, Cavalier E, Krzesinski JM. Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum. Nephrol Dial Transplant 2009; 24:3593-3596.
22. Zolopa A, Ortiz R, Sax P, Brar I, Elion R, Wang H, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment #99LB, CROI 2013. Atlanta: Georgia; 2013.
23. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
24. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in hiv-infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012; 59:628-635.
25. Lipworth L, MummaMT, Cavanaugh KL, Edwards TL, Ikizler TA, Tarone ER, et al. Incidence and predictors of end stage renal disease among low-income blacks and whites. PLoS One 2012; 7:e48407.
26. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008; 197:1548-1557.
27. Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, et al. Clinical epidemiology of HIV-associated end-stage renal failure in the UK. AIDS 2009; 23:2517-2521.
28. Ryom L, Kirk O, Lundgren J, Reiss P, Pedersen C, De Wit S, et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013; 14:503-508.
29. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S, et al. Kidney stones and kidney function loss: a cohort study. BMJ 2012; 345:e5287.
30. Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, et al. High incidence of renal stones among HIVinfected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262-1269Epub 2012 Jul 19.
31. FDA. Drug Approval Package Kaletra (Lopinavir/Ritonavir) Capsules & Oral Solution. Available at http://www.accessdata.fda.-gov/drugsatfda-docs/nda/ 2000/21-226-Kaletra.cfm; 2000. [Accessed on 9 January 2013]
32. FDA. Drug Approval Package VIREAD (Tenofovir Disoproxil Fumarate) Tablets.Available at. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21- 356-Viread.cfm; 2001. [Accessed on 9 January 2013]
33. FDA. FDA Approves Atazanavir, a Once Daily Protease Inhibitor for HIV Infection. Available at http://www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/HIVandAIDS Activities/ucm125077.htm; 2003. [Accessed on 9 January 2013]
34. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011, #A-452-0076-16167. Washington: IAS; 2012.
35. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17:2275-2284.
36. Bash LD, Astor BC, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010; 55:31-41.
37. Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 2012; 60:393-399.
38. Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P, et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med 2012; 14:127-135.
39. Deti EK, Thiebaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 2010; 11:308-317.
40. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007; 18:2758-2765.
41. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007; 72:1380-1387.